10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $958M | -$288M | 0.0% | -31.3% | -$190M | $340M | $199M |
| 2024 | $180M | -$466M | 96.5% | -276.4% | -$457M | $118M | $100M |
| 2023 | $0 | -$374M | — | — | -$326M | $115M | $100M |
| 2022 | $0 | -$295M | — | — | -$225M | $70M | $332M |
| 2021 | — | -$242M | — | — | -$184M | $0 | $36M |
| 2020 | — | -$202M | — | — | -$158M | — | $54M |
| 2019 | — | -$84M | — | — | -$42M | — | $47M |
| 2018 | — | -$33M | — | — | -$26M | — | $57M |
| 2017 | — | -$31M | — | — | -$22M | — | $149M |
| 2016 | — | -$26M | — | — | -$18M | — | $19M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $311M | -$94M | 0.0% | -29.8% | -$171M | $340M | $227M |
| Dec '25 | $321M | -$59M | 0.0% | -18.6% | -$133M | $340M | $199M |
| Sep '25 | $287M | -$114M | 0.0% | -39.7% | $79M | $340M | $296M |
| Jun '25 | $213M | -$42M | 0.0% | -22.2% | -$47M | $118M | $186M |
| Mar '25 | $137M | -$73M | 96.7% | -57.8% | -$89M | $118M | $184M |
| Dec '24 | $103M | -$59M | 0.0% | -64.8% | -$105M | $118M | $100M |
| Sep '24 | $62M | -$107M | 0.0% | -187.1% | -$68M | $117M | $233M |
| Jun '24 | $15M | -$152M | 0.0% | -1110.4% | -$135M | $117M | $495M |
| Mar '24 | $0 | -$148M | — | — | -$150M | $116M | $623M |
| Dec '23 | $0 | -$112M | — | — | -$81M | $115M | $100M |
| Sep '23 | $0 | -$99M | — | — | -$85M | $149M | $62M |
| Jun '23 | $0 | -$86M | — | — | -$75M | $132M | $77M |
| Mar '23 | — | -$77M | — | — | -$84M | $114M | $113M |
| Dec '22 | — | -$86M | — | — | -$59M | $70M | $332M |
| Sep '22 | — | -$81M | — | — | -$59M | $68M | $59M |
| Jun '22 | — | -$71M | — | — | -$57M | $67M | $53M |
| Mar '22 | — | -$58M | — | — | -$50M | — | $42M |
| Dec '21 | — | -$65M | — | — | -$48M | $0 | $36M |
| Sep '21 | — | -$63M | — | — | -$46M | — | $49M |
| Jun '21 | — | -$62M | — | — | -$47M | — | $34M |
How the market has priced MDGL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Madrigal Pharmaceuticals, Inc.'s multi-year trend.
As of FY2025, Madrigal Pharmaceuticals, Inc. reported $340M of total debt against $199M of cash; operating income covered interest expense -13.5×.
In FY2025, gross margin was —, operating margin -31.3%, and net margin -30.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.